AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03367013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Intervention includes a daily dose of 200 mg/kg bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
Study NCT03367013 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Bovine Lactoferrin added
Description: Control includes daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
Study NCT04265287 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Demographic, clinical, microbiological, critical care support and management data will be collected.
Study NCT01279109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network building intervention
Description: Group support and 12 weekly health education/skills building sessions during pregnancy
Study NCT01279109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home visit
Description: Three home visits during pregnancy focused on providing education on infant injury prevention
Study NCT01806311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan32mg
Study NCT01806311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine10mg
Study NCT02587806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow-Derived Mononuclear Stem Cells
Description: Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
Study NCT02587806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberation therapy
Study NCT03171324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: 2 mg/kg/day elemental iron
Study NCT04129762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet without NCS
Description: A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS.
Study NCT04129762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet with NCS
Description: A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS.
Study NCT05213403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation with new scoring system
Description: Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes
Study NCT04282746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54135419
Description: Single dose of JNJ-54135419 oral solution will be administered sublingually.
Study NCT01471262 — intervention group
Intervention type: PROCEDURE
Intervention: Right hepatectomy
Description: Right liver resection
Study NCT06708923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Name: Acupuncture Therapy Before and After Embryo Transfer Description: The intervention involves acupuncture therapy performed at two key time points during the IVF cycle: 25 minutes be
Description: Acupuncture Therapy Before and After Embryo Transfer~This intervention consists of acupuncture sessions designed to support implantation and improve pregnancy outcomes during frozen embryo transfer (FET) cycles.~Procedure:~Acupuncture is performed using sterile, single-use needles by certified practitioners trained in reproductive health.~Sessions occur at two critical time points:~Before Embryo Transfer: A 25-minute session targeting acupoints such as Baihui (DU20), Guanyuan (CV4), and Sanyinjiao (SP6) to enhance endometrial receptivity and reduce stress.~After Embryo Transfer: A second 25-minute session targeting acupoints such as Zusanli (ST36) and Taichong (LR3) to promote implantation and relaxation.~Purpose:~Improve uterine blood flow and receptivity. Regulate hormonal balance to optimize the implantation environment. Reduce psychological stress associated with IVF procedures. This intervention is compared retrospectively to standard IVF protocols without acupuncture to asses
Study NCT03786770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection
Study NCT04158687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Administered as powder for oral solution.
Study NCT03638180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: BLU-5937 oral tablet
Study NCT03638180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to BLU-5937
Study NCT03148275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03148275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT06350474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of dornase alfa (Dnase)
Description: Discontinuation of current dornase alfa (Dnase) therapy during 6-week study period.
Study NCT06350474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of dornase alfa (Dnase)
Description: Continuation of current dornase alfa (dnase) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily)
Study NCT04268550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Given PO
Study NCT02675114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAVR
Description: SAVR with a commercially available bioprosthetic valve.
Study NCT02675114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 THV
Description: TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
Study NCT02546115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tension night splint
Description: this is the use of a commercially available tension night splint device, to be worn by the patient
Study NCT02546115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard practice - a structured rehabilitation programme
Description: this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
Study NCT01702831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
Study NCT01702831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2
Study NCT01702831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
Study NCT01343927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly yoga classes
Description: Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
Study NCT01343927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual physical therapy treatment
Description: 12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
Study NCT01343927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care.
Study NCT02026960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNA extraction and amplification from biopsy specimens
Study NCT03152032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-House Vocational Training Programs
Description: At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
Study NCT04233034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HCL
Description: Hybrid Closed Loop therapy
Study NCT04233034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil 120mg tablet
Description: verapamil tablet
Study NCT04233034 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-HCL
Description: Usual diabetes care
Study NCT04233034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-HCL
Description: Usual diabetes care
Study NCT04233034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo pill manufactured to mimic verapamil 120mg tablet
Study NCT04233034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill manufactured to mimic verapamil 120mg tablet
Study NCT02135159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM1
Description: administration of the TDM1 by IV perfusion
Study NCT02135159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain Sequential RT
Description: local RT
Study NCT02360215 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy with hippocampal avoidance
Description: Intensity modulated radiation therapy (IMRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately two week; starting within 21 calendar days after randomization.
Study NCT01471262 — intervention group
Intervention type: PROCEDURE
Intervention: Extended right hepatectomy
Description: Right hepatectomy involving 5 or more segments
Study NCT03768245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education and Physical activity program
Description: Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
Study NCT03768245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education and Physical activity program
Description: Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
Study NCT03768245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Program
Description: Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
Study NCT02360215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Given PO daily during and after radiation therapy for a total of 24 weeks. Week 1: 5 mg in the AM, none in the PM; Week 2: 5 mg in the AM, 5 mg in the PM; Week 3: 10 mg in the AM, 5 mg in the PM; Weeks 4-24: 10 mg in the AM, 10 mg in the PM. Should start the same day as radiation therapy, at latest before the fourth radiation treatment.
Study NCT02360215 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy
Description: Whole brain radiation therapy (WBRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately 2 weeks
Study NCT00562627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: intraoperative and 1. postoperative day
Study NCT04158687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as powder for oral solution.
Study NCT01217580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Description: 20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
Study NCT01217580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
Study NCT01660295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 IU Once Daily
Description: Certoparin 3,000 IU subcutaneous injection once daily
Study NCT01660295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 IU Twice a Day
Description: Certoparin 3,000 IU subcutaneous injection twice a day
Study NCT01660295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 8,000 IU Once Daily
Description: Certoparin 8,000 IU subcutaneous injection once daily
Study NCT01660295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certoparin 8,000 IU Twice a Day
Description: Certoparin 8,000 IU subcutaneous injection twice a day
Study NCT00624104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Food (fat free meal)
Description: Fat free meal (40% of REE)
Study NCT00562627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adrenaline
Description: intraoperative LIA (IV and IA) and continuous EDA
Study NCT00406809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.
Study NCT00562627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline
Description: intraoperative LIA (IV and IA) and continuous EDA
Study NCT02595307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pamphlet
Description: Written pamphlet outlining the risks of surgery as discussed in consultation.
Study NCT00038792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Keratinocyte Growth Factor
Study NCT00550472 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
Study NCT04907448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks.
Study NCT04907448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks.
Study NCT01021878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icodextrin
Description: glucose sparing dialysis solution
Study NCT01021878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dianeal
Description: glucose based dialysis solution
Study NCT02387203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrevPac (Prevacid, Amoxicillin, Clarithromycin)
Description: 30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
Study NCT02892409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin tablets
Study NCT02892409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablets
Study NCT02892409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin capsules
Study NCT00562627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: intraoperative and 1. postoperative day
Study NCT02892409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin capsules
Study NCT02892409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tripotassium bismuth dicitrate
Description: Tripotassium bismuth dicitrate tablets
Study NCT02892409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripotassium bismuth dicitrate
Description: Tripotassium bismuth dicitrate tablets
Study NCT02892409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT02892409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study NCT01876043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plitidepsin
Description: Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~* Stage 1(17 participants): if \<=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~* Stage 2 (37 participants): if >= 11 non-progressions, Aplidin was considered promising.
Study NCT01532050 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mandibular Advancement Device ( MAD)